Scarica l'app Stockscreener
15.68
0.77%
0.12
Precedente Chiudi:
$15.56
Aprire:
$15.73
Volume 24 ore:
387.08K
Relative Volume:
0.28
Capitalizzazione di mercato:
$465.83M
Reddito:
$53.74M
Utile/perdita netta:
$33.24M
Rapporto P/E:
5.8877
EPS:
2.6632
Flusso di cassa netto:
$-27.40M
1 W Prestazione:
+3.50%
1M Prestazione:
+23.08%
6M Prestazione:
+304.12%
1 anno Prestazione:
+606.31%
Intervallo 1D:
$15.00
$15.99
Intervallo di 1 settimana:
$14.39
$16.61
Portata 52W:
$1.5685
$23.57
Q 32 Bio Inc Stock (QTTB) Company Profile
Nome
Q 32 Bio Inc
Settore
Industria
Telefono
781-999-0232
Indirizzo
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
15.68 | 451.87M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | Raymond James | Strong Buy |
| 2024-09-11 | Iniziato | Wells Fargo | Overweight |
| 2024-06-17 | Iniziato | Guggenheim | Buy |
| 2024-05-21 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Piper Sandler | Overweight |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Reiterato | BTIG Research | Neutral |
| 2022-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2020-12-14 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Iniziato | Chardan Capital Markets | Buy |
| 2019-11-01 | Iniziato | Oppenheimer | Perform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Q 32 Bio Inc Borsa (QTTB) Ultime notizie
H.C. Wainwright raises Q32 Bio stock price target to $36 on alopecia drug outlook - Investing.com
Q32 Bio Inc (QTTB) Balance Sheet - TradingKey
Q32 Bio Inc (QTTB) Income Statement - TradingKey
Q32 Bio Inc (QTTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q32 Bio Inc (QTTB) Cash Flow - TradingKey
QTTB|Q32 Bio Inc|Price:15.060|Chg%:-0.150 - TradingKey
QTTB|Q32 Bio Inc|Price:15.140|Chg%:-0.010 - TradingKey
Q32 Bio Inc (QTTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Q32 Bio Inc (QTTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Q32 Bio Inc (QTTB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q32 Bio Inc (QTTB) Institutional Confidence - TradingKey
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q32 Bio Inc (NASDAQ: QTTB) Stock Price, News & Analysis - Kalkine
Q32 Bio Inc Revenue Breakdown – DUS:DB0 - TradingView
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q32 Bio (QTTB) awards 10,826 stock options to director - Stock Titan
Q32 Bio (QTTB) corrects director’s 10,826 stock option award in Form 4/A - Stock Titan
Stock option grant for Q32 Bio Inc. (QTTB) director corrects prior award - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Q32 Bio Inc For: 21 July By Investing.com - Investing.com Canada
Form 13D/A Q32 Bio Inc. For: 21 July By Investing.com - Investing.com Canada
OrbiMed reports 13.9% Q32 Bio ownership and 45-day lock-up (QTTB) - Stock Titan
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - Yahoo Finance
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio files prospectus for offer and resale of 6.875M shares - scanx.trade
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Q32 Bio: Bempikibart's Progress Keeps Me Bullish (NASDAQ:QTTB) - Seeking Alpha
Boxer Capital Management, LLC Acquires Significant Stake in Q32 Bio Inc - GuruFocus
Why is Q32 Bio stock falling Wednesday? - MSN
Q32 Bio Inc. Announces $300 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement Details and Legal Opinions Included – Minichart - Minichart
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Nigeria
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Why Is Q32 Bio Stock Falling Wednesday? - Benzinga
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Q32 Bio prices $200M public offering, shares fall - scanx.trade
Q32 Bio Prices $200 Million Share Sale to Accelerate Alopecia Areata Drug Development - finance.biggo.com
Q32 Bio prices $200M public offering to fund al... - Pluang
Q32 Bio Expects $200M Offering to Support Bempikibart Trials - Stock Titan
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
$100 Invested In Q32 Bio 5 Years Ago Would Be Worth This Much Today - Benzinga
Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme - BioPharma APAC
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Sahm
Q32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valued - Yahoo Finance
Q32 Bio delivers 23.91% average annual return over five years - scanx.trade
Mizuho raises Q32 Bio stock price target on alopecia drug data - Investing.com UK
Why Q32 Bio Stock Skyrocketed Today - The Motley Fool
Q32 Bio reports positive bempikibart trial data in alopecia areata - scanx.trade
Q32’s bempikibart starts to differentiate from JAK inhibitors in alopecia - BioCentury
Q 32 Bio Inc Azioni (QTTB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Q 32 Bio Inc Azioni (QTTB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Xu Diyong | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| ORBIMED ADVISORS LLC | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| Kalowski Lee | CFO and President |
Feb 25 '26 |
Sale |
4.51 |
3,995 |
18,035 |
35,943 |
| Morrison Jodie Pope | CEO |
Feb 25 '26 |
Sale |
4.51 |
9,896 |
44,675 |
89,104 |
| Violette Shelia M. | Chief Scientific Officer |
Feb 25 '26 |
Sale |
4.51 |
2,815 |
12,708 |
55,569 |
| Morrison Jodie Pope | CEO |
Dec 02 '25 |
Sale |
3.46 |
22,506 |
77,871 |
99,000 |
| Kalowski Lee | CFO and President |
Dec 02 '25 |
Sale |
3.46 |
9,072 |
31,395 |
39,938 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):